Skip to main content

Levobetaxolol ophthalmic Pregnancy and Breastfeeding Warnings

Levobetaxolol ophthalmic is also known as: Betaxon

Levobetaxolol ophthalmic Pregnancy Warnings

Levobetaxolol ophthalmic has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of teratogenicity, but increased post-implantation loss occurred at 12 mg/kg/day and an increased incidence of sternebrae malformations occurred at 4 mg/kg/day in rats and rabbits. There are no controlled data during human pregnancy. Levobetaxolol is only recommended for use during pregnancy when benefit outweighs risk.

See references

Levobetaxolol ophthalmic Breastfeeding Warnings

There are no data on the excretion of levobetaxolol into human milk. Racemic betaxolol has been reported to be excreted into human milk after oral administration. Other beta-blockers and topical timolol maleate are excreted in milk. In general, most experts recommend monitoring of nursing infants for signs and symptoms of beta-blockade, such as bradycardia and hypoglycemia. The manufacturer recommends caution when administering levobetaxolol ophthalmic to nursing women.

See references

References for pregnancy information

  1. "Product Information. Betaxon (levobetaxolol ophthalmic)." Alza (2001):

References for breastfeeding information

  1. "Product Information. Betaxon (levobetaxolol ophthalmic)." Alza (2001):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.